Transplantation characteristics
| . | Myeloablative, no., n = 83 . | Nonmyeloablative, no., n = 59 . |
|---|---|---|
| Mean age at transplantation, y (range, SD) | 39.8 (19-58) | 50.2 (19-64) |
| Recipient sex | 53 M, 30 F | 39 M, 20 F |
| Disease | ||
| ALL | 11 | 0 |
| AML | 43 | 25 |
| CLL | 0 | 3 |
| CML | 7 | 1 |
| HD | 1 | 3 |
| MDS | 1 | 1 |
| MM | 2 | 12 |
| CIMF | 1 | 0 |
| NHL | 11 | 13 |
| PRCA | 1 | 0 |
| SAA | 5 | 0 |
| Renal | 0 | 1 |
| Risk | ||
| Standard | 28 | 18 |
| High | 55 | 41 |
| Stem cell source | ||
| Peripheral blood | 77 | 57 |
| Bone marrow | 6 | 2 |
| Conditioning regimen | ||
| Busulphan plus cyclo | 23 | 0 |
| Busulphan plus cyclo plus etop | 2 | 0 |
| Busulphan plus melphalan | 1 | 0 |
| Cyclo-based chemotherapy* | 6 | 0 |
| Cyclo plus TBI/TNI | 43 | 1 |
| Etoposide plus TBI | 7 | 0 |
| Fludarabine plus cyclo | 1 | 25 |
| Fludarabine plus melphalan | 0 | 24 |
| Melphalan | 0 | 5 |
| Low-dose TBI | 0 | 4 |
| Immunosuppression | ||
| CsA/tacrolimus (± steroid) | 16 | 7 |
| CsA plus MMF (± steroid) | 0 | 6 |
| CsA/tacrolimus plus MTX (± steroid) | 64 | 45 |
| CsA plus MTX plus MMF plus steroid | 3 | 1 |
| Gut decontamination† | ||
| None | 46 | 23 |
| Norfloxacin | 19 | 25 |
| Ciprofloxacin and Metronidazole | 18 | 11 |
| CMV prophylaxis | ||
| Preemptive | 63 | 33 |
| Suppressive | 20 | 26 |
| . | Myeloablative, no., n = 83 . | Nonmyeloablative, no., n = 59 . |
|---|---|---|
| Mean age at transplantation, y (range, SD) | 39.8 (19-58) | 50.2 (19-64) |
| Recipient sex | 53 M, 30 F | 39 M, 20 F |
| Disease | ||
| ALL | 11 | 0 |
| AML | 43 | 25 |
| CLL | 0 | 3 |
| CML | 7 | 1 |
| HD | 1 | 3 |
| MDS | 1 | 1 |
| MM | 2 | 12 |
| CIMF | 1 | 0 |
| NHL | 11 | 13 |
| PRCA | 1 | 0 |
| SAA | 5 | 0 |
| Renal | 0 | 1 |
| Risk | ||
| Standard | 28 | 18 |
| High | 55 | 41 |
| Stem cell source | ||
| Peripheral blood | 77 | 57 |
| Bone marrow | 6 | 2 |
| Conditioning regimen | ||
| Busulphan plus cyclo | 23 | 0 |
| Busulphan plus cyclo plus etop | 2 | 0 |
| Busulphan plus melphalan | 1 | 0 |
| Cyclo-based chemotherapy* | 6 | 0 |
| Cyclo plus TBI/TNI | 43 | 1 |
| Etoposide plus TBI | 7 | 0 |
| Fludarabine plus cyclo | 1 | 25 |
| Fludarabine plus melphalan | 0 | 24 |
| Melphalan | 0 | 5 |
| Low-dose TBI | 0 | 4 |
| Immunosuppression | ||
| CsA/tacrolimus (± steroid) | 16 | 7 |
| CsA plus MMF (± steroid) | 0 | 6 |
| CsA/tacrolimus plus MTX (± steroid) | 64 | 45 |
| CsA plus MTX plus MMF plus steroid | 3 | 1 |
| Gut decontamination† | ||
| None | 46 | 23 |
| Norfloxacin | 19 | 25 |
| Ciprofloxacin and Metronidazole | 18 | 11 |
| CMV prophylaxis | ||
| Preemptive | 63 | 33 |
| Suppressive | 20 | 26 |
Standard risk was defined as acute myeloid leukemia in first remission and chronic myeloid leukemia in first chronic phase. All other diseases and stages were considered high risk.
Cyclo indicates cyclophosphamide; Etop, etoposide; TBI, total body irradiation; TNI, total nodal irradiation; CsA, cyclosporine A; MMF, mycophenolate mofetil; and MTX, methotrexate.
Includes cyclophosphamide alone (n = 3), or with ATG (n = 2) or lomustine, cytarabine and etoposide (n = 1).
Ciprofloxacin 750 mg twice daily, metronidazole 400 mg daily, norfloxacin 400 mg twice daily. Suppressive CMV prophylaxis was with regular intravenous ganciclovir or oral valaciclovir.